GlobeNewswire

Mimo Monitors Announces First European Office In the Netherlands, Showcasing a Commitment to Global Growth and Superior Customer Service

Dela

New European office located just outside Amsterdam to provide Mimo Monitors with the ability to serve international customers with ease

CHICAGO, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Mimo Monitors (www.MimoMonitors.com), the leader in small touch screen monitors, announced that they are opening a new office in Nieuwegein, just outside Amsterdam, expanding its presence in Europe and around the globe. On the cusp of Mimo Monitors' surpassing growth targets in this region and overall large sales growth in 2017, this new office will support Mimo Monitors' expansion across Europe and provide an additional touchpoint for international clients.

Additionally, this new European base will increase Mimo Monitors' ability to provide superior customer service to businesses in the region seeking touchscreen monitor solutions to enhance productivity and transform how they engage with customers.

"We are delighted to make our small touchscreen expertise more accessible to clients in Europe and continue to grow our business in a way that benefits our customers. This new office represents our commitment to Europe and we know we will have a positive future globally," said David Anderson, President and Founder of Mimo Monitors. "In addition to honoring our promise of 'touchscreens with human touch', this global expansion allows us to continue growing our talented team who can help tell the Mimo Monitors story, and provide top-notch customer service."

Mimo Monitors has added Remco Bon to the team who joins with more than 25 years of global experience in ICT/Telecom sales and sales management. He will lead the Amsterdam office and provide sales and support for European customers.

"I'm pleased to be heading up an office in Amsterdam with the goal of continuing to grow Mimo Monitors' business on an international scale," said Remco Bon, Head of Sales for the Amsterdam office. "We're dedicated to offering our unique and flexible expertise in the small touchscreen arena while providing ongoing one-on-one support to exceed our client's needs."

The Mimo Monitors Netherlands office opened in January 2018, and marks the first European office for Mimo Monitors, adding to offices in North America and South Korea. This global expansion comes after of a great year of growth for Mimo Monitors in 2017, who recently announced collaborations with both Google and Logitech. The Mimo Monitors Amsterdam office is located at: Galvanibaan 4, 3439 MG Nieuwegein, Netherlands and can be reached at +31(0)20 299 0160.

About Mimo Monitors:

Mimo Monitors, established in 2008, is a global expert and industry leader in small touchscreen monitors, displays, and tablets. Designed with a solutions-first approach, Mimo Monitors believes in creating small footprint, high value displays that drive innovation and provide a seamless experience for digital signage, conference rooms, kiosks, point of purchase, point of sale, hospitality, and more. The Mimo Monitors world-class team has deployed Mimo Monitors solutions in locations throughout the world for Fortune 500 companies, both in the US and around the world.

http://www.globenewswire.com/NewsRoom/AttachmentNg/4c9d4895-609a-4dd6-a983-8f522a441d9f

dana@spokeandwheelstrategy.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mimo Monitors via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Immunicum AB (publ) meddelar kommande konferenser i mars och april22.3.2019 08:00:00 CETPressmeddelande

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledningsgruppen kommer att delta och presentera vid kommande konferenser i mars och april. BIO-Europe Spring Datum: 25-27 mars 2019 Plats: Messe Wien Exhibition and Congress Center, Wien, Österrike Deltagare: Sijme Zeilemaker China Focus @ Europe Vienna Datum: 27 mars 2019 Paneltid/Sessionstid: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Plats: Hilton Vienna Danube Waterfront, Wien, Österrike Deltagare: Carlos de Sousa Swedish American Life Science Summit 2019 Datum: 9-10 april 2019 Presentationsdatum: Onsdagen 10 april 2019 Plats: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Deltagare: Carlos de Sousa För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@i

Immunicum AB (publ) Announces Upcoming Conferences in March and April22.3.2019 08:00:00 CETPressmeddelande

Press Release 22 March 2019 Immunicum AB (publ) Announces Upcoming Conferences in March and April Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in March and April. BIO-Europe Spring Date: March 25-27, 2019 Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria Participant: Sijme Zeilemaker China Focus @ Europe Vienna Date: March 27, 2019 Panel Time/Session: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Venue: Hilton Vienna Danube Waterfront, Vienna, Austria Participant: Carlos de Sousa Swedish American Life Science Summit 2019 Date: April 9-10, 2019 Presentation Date: Wednesday, April 10, 2019 Venue: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Participant: Carlos de Sousa For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum